Ivpex Parenteral Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 2.50 Cr
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.31 Cr
- Revenue Growth %
- Profit Growth 146.58%
- Ebitda 1957.12%
- Net Worth 8237.14%
- Total Assets 40.25%
About Ivpex Parenteral
Ivpex Parenteral Private Limited (IPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 October 2019 (Five years and three months 23 days old ). Its registered office is in Solan, Himachal Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹10.31 Cr.
Binod Agarwal and Kaushalendra Sharma serve as directors at the Company.
Company Details
-
Location
Solan, Himachal Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U33100HP2019PTC007663
-
Company No.
007663
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Oct 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Himachal Pradesh
Industry
Who are the key members and board of directors at Ivpex Parenteral?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Binod Agarwal
|
Director | 23-Oct-2019 | Current |
|
Kaushalendra Sharma
|
Director | 23-Oct-2019 | Current |
Financial Performance of Ivpex Parenteral.
Ivpex Parenteral Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 146.58% increase in profit. The company's net worth Soared by an impressive increase of 8237.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ivpex Parenteral?
Unlock access to Ivpex Parenteral's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Ivpack Parenteral Private LimitedKaushalendra Sharma is a mutual person
Charges (Loans)
₹10.31 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 10.31 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Mar 2024 | Others | ₹3.08 M | Open |
| 31 Aug 2021 | Others | ₹10.00 Cr | Open |
How Many Employees Work at Ivpex Parenteral?
Ivpex Parenteral has a workforce of 34 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ivpex Parenteral, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ivpex Parenteral's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.